InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,663.60
(
0.13%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
83.89
(
-0.08%
)
Bitcoin
62,964.75
(
-0.13%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

medichem

Send PM Follow Ignore
Followers 0
Posts 1
Boards Moderated 0
Alias Born 12/05/2016

medichem

Re: biotech_researcher post# 79332

Monday, 12/05/2016 9:08:02 PM

Monday, December 05, 2016 9:08:02 PM

Post# of 80490
about 788, from a medichem point of view, it is very close analogue of AZ9291. The only difference is in the indole part, which affect its binding to the so called back pocket. IF AZ9291 is successful, I think 788 will also be successful. so I don't think Ariad will be sold until 788 shoewed its potential....you may call it me too or me better version of AZ9291, but there are some differentiation, just like Bragtinib
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up